# A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

> **NCT02514681** · PHASE3 · COMPLETED · sponsor: **Japan Breast Cancer Research Group** · enrollment: 226 (actual)

## Conditions studied

- HER2-positive Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Vinorelbine
- **DRUG:** Eribulin
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02514681
- **Lead sponsor:** Japan Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2022-08-10
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02514681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02514681, "A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02514681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*